期刊
RADIOTHERAPY AND ONCOLOGY
卷 167, 期 -, 页码 239-243出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2021.12.032
关键词
Nasopharyngeal carcinoma; Intensity-modulated radiotherapy; Elective neck irradiation; Level Ib
资金
- National Key Clinical Specialty Construction Program
- Key Clinical Specialty Discipline Construction Program of Fujian, China
- Fujian Provincial Natural Science Foundation of China [2019J01194]
- Joint Funds for the innovation of science and Technology, Fujian province [2018Y9109, 2018Y9114]
- Fujian Provincial Health Technology Project [2020GGA014, 2020GGB013]
- Joint research project of health and education of Fujian Province [2019-WJ-02]
- Fujian Provincial Clinlical Research Center for Cancer Radiotherapy and Immunotherapy [2020Y2012]
This study investigated the feasibility of level Ib sparing in selected nasopharyngeal carcinoma patients during intensity-modulated radiation therapy based on the International Guideline. The results showed that level Ib-sparing IMRT is safe and feasible for patients who meet certain criteria.
Background and purpose: To investigate the feasibility of level Ib sparing in selected nasopharyngeal carcinoma (NPC) patients during intensity-modulated radiation therapy (IMRT) based on the International Guideline. Patients and materials: Patients with histologically-proven NPC who received definitive IMRT at our group were candidates for this analysis. Other eligibility criteria for analysis were designed according to the recommendation of International Guideline for selective coverage of level Ib. Survival outcomes focused on regional recurrence-free survival (RRFS) and level Ib recurrence rate were analyzed. Results: A total of 450 patients were included, 60 of them received level Ib-covering IMRT due to the first three principles of the International Guideline according to our protocol. Of note, patients with level Ib involvement would receive ultrasound guided puncture, only those with positive pathological results would undergo level Ib-covering IMRT. For the remaining 390 patients who only fulfilled the last two criteria and/or level Ib involvement with negative pathological results, level Ib-sparing IMRT was delivered, with a median follow-up time of 112 months (range 6 to 194 months), reported 5- and 10-year RRFS were 95.4% and 92.9%, respectively. Twenty-two patients occurred regional recurrence at censorship (median 44.5 months), only 4(4/390, 1.03%) were recorded as level Ib recurrence. Conclusion: Level Ib-sparing IMRT should be safe and feasible for patients who only had level II involvement with ECE, and/or had a MAD of greater than 2 cm in level II, and/or level Ib involvement with negative pathological results. Further well-designed multi-center prospective trials should be conducted. (C) 2022 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据